Ivonescimab for lung cancer fails cost-effectiveness test in China at current prices
A new economic evaluation published in BMC Health Services Research concludes that ivonescimab plus chemotherapy, an emerging first-line option for ...
Tag: non-small-cell
POPULAR NEWS
-
Ivonescimab for lung cancer fails cost-effectiveness test in China at current prices
-
Tumor Cell PD-L1 Score Predicts Longer Survival in Gastric Cancer Treated with Chemotherapy Alone
-
Gut Infections Leave Long-Lasting Immune Memory at the Brain’s Border
-
How Antiviral Innate Immunity Shapes Viral Myocarditis Outcomes